Latest News

BioStem Technologies: CMS Decision a “Win For Patients”

 “We have already demonstrated scientifically that our process and product is exceptional.”Jason Matuszewski, Chief Executive OfficerSeptember 26, 2023BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical...

Translate »